

ASX Announcement

Optiscan Imaging Limited (ASX:OIL)

16 April 2018

Successful European conference participation

Optiscan Imaging Limited (ASX:OIL; “Optiscan” or “The Company”) is pleased to provide shareholders with this market update following the Company’s successful participation at the EMIM Conference in Spain last month.

Successful participation at the EMIM Conference

The 13th European Molecular Imaging Meeting (EMIM), held in Spain last month attracted more than 700 delegates. The conference provided Optiscan with the opportunity to reinforce our re-entry to the preclinical research market following our participation at the World Molecular Imaging Congress in the USA last September.

As a platinum sponsor at EMIM, Optiscan utilised prime exhibition space, multiple advertising mediums and a presentation opportunity to connect with potential customers and European distribution partners.

The conference was attended by Andrew Froude (General Manager - Preclinical Research Products) and Peter Delaney (CTO) along with representatives of the Optiscan distributors of our leading high-resolution point scanning confocal technology, *ViewnVivo*.

Interest from conference delegates in Optiscan’s *ViewnVivo* technology was strong with 39 leads captured including 28 identified as potential customers. Six potential customers have already requested meetings and product demonstrations.

“This is a direct reflection of the continued tremendous efforts of Andrew Froude over the past 20 months, having driven the *ViewnVivo* product development and successfully created penetration into the market in this space” said Executive Chairman Alan Hoffman.

Andrew Froude is also attending events and meeting with customers in China, USA and Canada over the next month to continue the push into these crucial markets for *ViewnVivo* highlighting the value of a continued good relationship with our distributors in North America and China.

Optiscan looks forward to sharing more updates with the market on a range of developments in coming weeks.

Enquiries:

Alan Hoffman

Executive Chairman

E: ahoffman@optiscan.com

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes and is now a global leader in the development and application of microscopic imaging technologies for Preclinical Research in science and life sciences as well as medical markets, such as neurosurgery. With the high cost of curative medicine, an opportunity exists for Optiscan’s technology to be used globally to reduce costs and be used as a key tool for the early detection of disease, the effective treatment of disease and the improvement of treatment outcomes.